JP2020512315A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512315A5
JP2020512315A5 JP2019550579A JP2019550579A JP2020512315A5 JP 2020512315 A5 JP2020512315 A5 JP 2020512315A5 JP 2019550579 A JP2019550579 A JP 2019550579A JP 2019550579 A JP2019550579 A JP 2019550579A JP 2020512315 A5 JP2020512315 A5 JP 2020512315A5
Authority
JP
Japan
Prior art keywords
hydrogen
deuterium
disease
fibrosis
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019550579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512315A (ja
JP7200120B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022544 external-priority patent/WO2018170200A1/en
Publication of JP2020512315A publication Critical patent/JP2020512315A/ja
Publication of JP2020512315A5 publication Critical patent/JP2020512315A5/ja
Application granted granted Critical
Publication of JP7200120B2 publication Critical patent/JP7200120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019550579A 2017-03-16 2018-03-15 Mk2阻害剤として有用なヘテロアリール化合物 Active JP7200120B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472019P 2017-03-16 2017-03-16
US62/472,019 2017-03-16
PCT/US2018/022544 WO2018170200A1 (en) 2017-03-16 2018-03-15 Heteroaryl compounds useful as mk2 inhibitors

Publications (3)

Publication Number Publication Date
JP2020512315A JP2020512315A (ja) 2020-04-23
JP2020512315A5 true JP2020512315A5 (https=) 2021-04-30
JP7200120B2 JP7200120B2 (ja) 2023-01-06

Family

ID=63523329

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550579A Active JP7200120B2 (ja) 2017-03-16 2018-03-15 Mk2阻害剤として有用なヘテロアリール化合物

Country Status (4)

Country Link
US (2) US11124525B2 (https=)
EP (1) EP3596083A4 (https=)
JP (1) JP7200120B2 (https=)
WO (1) WO2018170200A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN115925718A (zh) * 2022-12-27 2023-04-07 瑞石生物医药有限公司 一种四环内酰胺衍生物及其用途
WO2024229401A2 (en) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Diazepino-thieno-quinoxaline compounds and their use in therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
ES2293638T3 (es) * 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
WO2016032882A1 (en) 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
RS62017B1 (sr) * 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体

Similar Documents

Publication Publication Date Title
JP2020512315A5 (https=)
JP2020511468A5 (https=)
JP2020514361A5 (https=)
JP2020514360A5 (https=)
JP2024113019A5 (https=)
CN109071448B (zh) Ask1抑制剂及其制备方法和应用
TWI847144B (zh) 奧美卡替莫卡必爾的合成
JP2019524660A5 (https=)
JP2013545812A5 (https=)
JP2011513485A5 (https=)
JP2008510762A5 (https=)
JP2022531088A5 (https=)
CA3019450A1 (en) Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application
Chen et al. Controlled crystallization of anhydrous guanine β nano-platelets via an amorphous precursor
JP2009502961A5 (https=)
CN112955453B (zh) 作为选择性Trk抑制剂的吡唑并嘧啶衍生物
CN117486959A (zh) 磷酸酯衍生物的合成
EP3733184B1 (en) Pyrimidine compounds for use in the treatment of cancer
WO2009082846A1 (fr) Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
JP2007506765A5 (https=)
TWI703163B (zh) 舒更葡糖鈉之製備方法及其晶型
CN112752749B (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN112585124B (zh) 用于合成sglt抑制剂的中间体的制备方法
WO2012139522A1 (zh) 去氢木香烃内酯衍生物,其药物组合物及其制备方法和用途
JP2006525367A5 (https=)